Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
MRI-guided In-bore vs MRI-transrectal Ultrasound Fusion PCa Biopsies
Key clinical point: In-bore biopsies detected more aggressive cancers and fewer indolent cancers than fusion biopsies.
Major finding: In-bore biopsies detected a higher proportion of csPCa (61%, 63/103) than fusion plus systematic biopsies (47%, 141/300; adjusted odds ratio [OR]: 2.1, 95% confidence interval [CI]: 1.6-2.8, p<0.0001), and also detected fewer (11%, 11/103) clinically insignificant cancers than fusion biopsies (18%, 53/300; OR: 0.5, 95% CI: 0.3-0.8, p=0.001).
Study details: A retrospective analysis of prospectively generated data included 403 men with abnormal mpMRI and fusion or in-bore biopsy between May 2017 and April 2018.
Costa DN, et al. Eur Urol Oncol. 2019 Jul;2(4):397-404. doi: 10.1016/j.euo.2018.08.022.